News | September 30, 2013

Average Phase I Trial Costs Approach $9,000 Per Patient Per Month

Neurology trials cost the most at $8,943 per patient per month, found Cutting Edge Information

September 30, 2013—A study by Cutting Edge Information found that pharmaceutical companies measure cost per patient per month to allow trials of different sizes and durations to be compared easily. This measurement also helps to illustrate the high costs associated with delays.

The study, “Phase I Clinical Trials: Optimizing Cost-Drivers for Clinical Pharmacology Programs,” found that neurology and central nervous system (CNS) trials cost the most at $8,943 per patient per month. The trials’ high price tag, combined with a relatively short average duration of 9.6 months helps CNS top the list among all surveyed therapeutic areas.

Surveyed cardiology and respiratory Phase I trials’ short average durations (8.6 months and 5 months, respectively) help to elevate these therapeutic areas above oncology in terms of cost per patient per month. In fact, oncology trials’ relatively average long duration (36 months) gives the therapeutic area an average cost per patient per month of $2,822.

The research team at Cutting Edge Information analyzed cost per patient per month data for oncology, cardiology, CNS and gastroenterology trials. The following are highlights from each therapeutic area:

  • An oncology trial reported the second highest cost per patient per month ($20,635) of all trials in this study behind only one CNS trial.
  • A cardiology trial, which incurred the lowest cost per patient per month at $2,375, lasted five months longer than the other trials studied. This is a rare instance when shorter trials incur higher total costs — likely the result of imaging procedures built into their protocol.
  • CNS trials have the widest range of costs per patient per month at $20,606.
  • Gastroenterology trials report the narrowest range of cost per patient per visit — only $347.
  • “Phase I Clinical Trials: Optimizing Cost-Drivers for Clinical Pharmacology Programs,” (http://www.cuttingedgeinfo.com/research/clinical-development/phase-i-clinical-trials/) examines the critical cost drivers when budgeting for Phase I trials. Use this report to:
  • Manage critical cost-drivers when budgeting for Phase I trials.
  • Save time and prevent costly delays with early strategic planning.
  • Balance the number and quality of trial sites during site selection to manage patient enrollment and drop-off rates.

For more information: http://www.cuttingedgeinfo.com/research/clinical-development/phase-i-clinical-trials/

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init